Pearl River Capital’s Royalty Pharma RPRX Stock Holding History

Pearl River Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-24,062	Closed	-$635K	–	306
2024 Q2	$635K	Sell	24,062 -46,531	-66%	-$1.29M	0.1%	243
2024 Q1	$2.14M	Buy	70,593 +19,146	+37%	+$564K	0.34%	91
2023 Q4	$1.45M	Sell	51,447 -17,072	-25%	-$469K	0.23%	133
2023 Q3	$1.86M	Sell	68,519 -8,990	-12%	-$267K	0.29%	116
2023 Q2	$2.38M	Buy	+77,509	New	+$2.63M	0.38%	77
2023 Q1	–	Sell	-36,796	Closed	-$1.45M	–	603
2022 Q4	$1.45M	Buy	36,796 +5,900	+19%	+$246K	0.25%	128
2022 Q3	$1.24M	Buy	+30,896	New	+$1.32M	0.23%	141
2022 Q2	–	Sell	-23,024	Closed	-$897K	–	549
2022 Q1	$897K	Buy	23,024 +2,724	+13%	+$107K	0.25%	126
2021 Q4	$809K	Buy	20,300 +10,878	+115%	+$423K	0.22%	149
2021 Q3	$341K	Sell	9,422 -10,547	-53%	-$410K	0.09%	288
2021 Q2	$819K	Buy	+19,969	New	+$849K	0.23%	148

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pearl River Capital's RPRX Position: Q3 2024 in Review

Pearl River Capital sold out of Royalty Pharma (RPRX) in Q3 2024, closing a stake of 24,062 shares — an estimated $635K sold.

Pearl River Capital first reported a position in RPRX in Q2 2021 and held it in 11 quarters. The position peaked at $2.38M in Q2 2023. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

Pearl River Capital reported no remaining Royalty Pharma position as of Q3 2024 after selling out during the quarter.
Pearl River Capital sold 24,062 Royalty Pharma shares in Q3 2024, an estimated $635K.
Pearl River Capital first reported a position in Royalty Pharma in Q2 2021 and held it in 11 quarters.
Pearl River Capital's Royalty Pharma position peaked at $2.38M in Q2 2023.
395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on Pearl River Capital's 13F filing for Q3 2024.